Chemotherapy Observation or Inpatient Hospitalization

Policy Number: MP.02.15
Effective Date: October 1, 2023

Application

UnitedHealthcare Commercial
This Medical Policy applies to all UnitedHealthcare Commercial benefit plans.

UnitedHealthcare Individual Exchange
This Medical Policy applies to Individual Exchange benefit plans in all states except for Colorado.

Coverage Rationale

Note: This policy does not apply to individuals under 18 years of age.

Most cancer chemotherapies can be administered safely and effectively in a physician's office or through home healthcare services. However, because of the risk of certain toxicities or individual comorbidities, some cancer chemotherapy may be administered either in a facility observation or inpatient unit.

An inpatient stay is medically necessary for drug regimens that require inpatient monitoring or complex administration over multiple days:

<table>
<thead>
<tr>
<th>Regimen</th>
<th>Drugs</th>
<th>Cancer Type</th>
<th>Factors contributing to the need for inpatient stay</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPOCH, DA-EPOCH or R-EPOCH</td>
<td>Etoposide 50 mg/m²/day continuous infusion on days 1 to 4&lt;br&gt;Prendisone&lt;br&gt;Vincristine (oncovine) IV days 1-4&lt;br&gt;Cyclophosphamide 750 mg/m² IV on day 5&lt;br&gt;Doxorubicin (hydroxydaunorubicin) 10 mg/m²/day continuous infusion on days 1-4&lt;br&gt;With or without Rituximab</td>
<td>Lymphoma</td>
<td>Coordination of multiple infusions or multiple drugs over 96 hours</td>
</tr>
<tr>
<td>Regimen</td>
<td>Drugs</td>
<td>Cancer Type</td>
<td>Factors contributing to the need for inpatient stay</td>
</tr>
<tr>
<td>---------</td>
<td>-------</td>
<td>-------------</td>
<td>---------------------------------------------------</td>
</tr>
</tbody>
</table>
| ESHAP or R-ESHAP | - Etoposide 40 mg/m²/day continuous infusion on days 1 to 4  
| | - Methylprednisolone (solumedrol)  
| | - Cytarabine ("high-dose Ara-c") 2g/m²  
| | - Cisplatin (platinol) 25mg/m² continuous infusion days 1-4  
| | - With or without Rituximab | Lymphoma | - Coordination of multiple infusions or multiple drugs over 96 hours  
| | | | - Monitor for CNS toxicity with cytarabine |
| Interleukin 2 infusion | - Interleukin 2 600,000 IU/kg IV every 8 hours for up to 14 consecutive doses over 5 days | Melanoma, Renal Cell Cancer | - Continuous cardiac monitoring  
| | | | - Close monitoring of serum electrolytes, creatinine, bilirubin, urine output  
| | | | - Vasopressor support with dopamine  
| | | | - Proximity to intensive care unit |
| High dose Ifosphamide | - Ifosphamide infusion > 1g/m²/day | Sarcoma | - Close monitoring of serum electrolytes and urine pH  
| | | | - Replacement of electrolytes  
| | | | - Alkalinization of urine |
| High dose methotrexate with leucovorin rescue | - Methotrexate dose at > 500 mg/m²  
| | | - Leucovorin 15 mg every 6 hours for eight doses beginning 12 hours after the completion of methotrexate infusion, and increased to 50 mg IV every 6 hours if methotrexate levels are > 20 µmol/L at 0 hour, are > 1.0 µmol/L at 24 hours, or are > 0.1 µmol/L at 48 hours after the end of methotrexate infusion, until levels are < 0.1 µmol/L plus  
| | | - Coordination of multiple infusions or multiple drugs over 96 hours  
| | | - Bladder irrigation with cyclophosphamide  
| | | - Close monitoring of serum methotrexate levels |
| Hyper-CVAD | Cycles 1, 3, 5, and 7 (3-4 weeks between cycles):  
| | - Cyclophosphamide 300 mg/m² IV over 2 hours every 12 hours for 6 doses  
| | - Mesna 600 mg/m²/day continuous infusion on days 1-3, starting 1 hour before cyclophosphamide  
| | - Vincristine  
| | - Doxorubicin 50 mg/m² IV on day 4  
| | - Dexamethasone | Lymphoma, Leukemia | - Coordination of multiple infusions or multiple drugs over 96 hours  
| | | | - Close monitoring of serum methotrexate levels  
| | Cycles 2, 4, 6, and 8 (3-4 weeks between cycles):  
| | - Methotrexate 200 mg/m² IV over 2 hours followed by 800 mg/m² IV over 22 hours on day 1 plus  
| | - Cytarabine 3 g/m² (1 g/m² for patients older than 60 years) IV over 2 hours every 12 hours for four doses starting on day 2  
| | - Leucovorin 15 mg every 6 hours for eight doses beginning 12 hours after the completion of methotrexate infusion, and increased to 50 mg IV every 6 hours if methotrexate levels are > 20 µmol/L at 0 hour, are > 1.0 µmol/L at 24 hours, or are > 0.1 µmol/L at 48 hours after the end of methotrexate infusion, until levels are < 0.1 µmol/L plus  
| | | | - Coordination of multiple infusions or multiple drugs over 96 hours  
| | | | - Bladder irrigation with cyclophosphamide  
| | | | - Close monitoring of serum methotrexate levels  
| | | - Methylprednisolone 50 mg |
The following are clinical conditions or complications of cancer chemotherapy which may require an observation stay:
- Known hypersensitivity reactions from previous infusion
- Congestive heart failure or chronic renal failure requiring high volume fluid infusions
- Transcatheter Arterial Chemoembolization (TACE) or intra-arterial chemotherapy infusion

The following are clinical conditions which require an inpatient hospital stay:
- Acute leukemia
- Intra-arterial infusion of chemotherapy
- Prophylaxis of tumor lysis syndrome in cases of high-grade lymphoma with large masses

Conditions requiring observation or inpatient hospital treatment other than those noted above will be reviewed on a case-by-case basis.

For medical necessity clinical coverage criteria in these instances, refer to the InterQual® LOC: Acute Adult, Hematology/Oncology: Chemotherapy.

Click [here](#) to view the InterQual® criteria.

Note:
- A written protocol will be expected to be followed by the provider administering the chemotherapy drug.
- Any requests for an extension of the inpatient stay beyond the recommended day(s) must be clinically reviewed.

 Definitions

**TACE (Transcatheter Arterial Chemoembolization):** A procedure in which the blood supply to a tumor is blocked after anticancer drugs are given in blood vessels near the tumor. (NCI, 2022)

**Description of Services**

Chemotherapy uses drugs to treat cancer curatively, or before (neoadjuvant) or after (adjuvant) other treatments such as surgery or radiation. It can also be used to slow cancer growth and relieve symptoms. Depending on a number of factors, including, but not limited to, the drugs being given, the route of administration, and a person’s condition, chemotherapy can be administered at home, in a provider’s office, an outpatient clinic, or in the hospital. (ASCO, 2022)

**Clinical Evidence**

Nelles et al. (2022) evaluated outcomes of treatment of double-hit lymphoma (DHL) with dose-adjusted etoposide, prednisolone, vincristine, cyclophosphamide, doxorubicin and rituximab (DA-EPOCH-R) in a retrospective cohort study. The authors conducted a retrospective study of 13 consecutive patients with DHL treated with DA-EPOCH-R in an outpatient tertiary center. Primary endpoints included complete response (CR), event-free survival (EFS) and overall survival (OS). Treatment was given in the outpatient setting where feasible, with admission to the inpatient unit as required for complications such as febrile neutropenia. CR rate with DA-EPOCH-R in DHL was 69% in the cohort. Median EFS and OS duration was 61 months (95% CI: 41-86 months) and 64 months (95% CI: 42-86 months) respectively. One patient discontinued DA-EPOCH-R due to recurrent febrile neutropenia and there were no treatment or infection-related deaths during the study. The authors concluded DA-EPOCH-R is a well-tolerated regimen for DHL that can be delivered primarily in an outpatient setting. They also noted that patient selection may be required to identify the cohort that are likely to tolerate dose escalation to derive full benefit from the protocol. The authors state that further prospective studies are warranted to confirm these findings. The study is limited by a small number of participants and variations in adjunctive treatment.

In a retrospective cohort study, Banh et al. (2021) sought to characterize and compare both the outcome and cost of treatment of outpatient (OP) and inpatient (IP) ifosfamide therapy. The authors performed a single-center retrospective chart review of patients 18 years and older receiving ifosfamide therapy. The primary endpoint compared and evaluated the side effect profiles of ifosfamide-treated patients in the OP/IP settings. The adverse event grading system was characterized using the Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. The highest grade was documented per cycle.
A retrospective cohort study was conducted to compare the costs of OP/IP therapy. Ifosfamide therapy of 86 patients (57 OP, 29 IP) was reviewed. The predominant OP regimens were doxorubicin-ifosfamide-mesna (AIM) with 43.9% and ifosfamide-etoposide (IE) with 29.8%. Grade 4 anemia, thrombocytopenia, and neutropenia were most frequent in IP vs OP therapies (22.9% IP vs 4.3% OP, 21.6% IP vs 9.2% OP, and 22.8% IP vs 19.6% OP respectively). Neutropenic fever (NF) occurred in 20 OP patients which were predominantly treated with AIM or IE and led to average hospital stay of 6 days. Neurotoxicity, treated with methylene blue occurred in 4 OP patients. OP therapy saved a total of 783 hospital days. The authors concluded transitioning ifosfamide to the OP setting is feasible for academic and community infusion centers with the OP administration being safe, well-tolerated, and associated with decreased total cost of care. This study was limited by a small sample size at a single institution and changes in the electronic medical record during the time period of the study. The authors also note that it is possible the patients who received therapy as an inpatient required closer monitoring increasing the number of adverse drug events reported.

In a retrospective cohort study, Li et al. (2020) compared IP and OP administration of dose-adjusted (DA-) EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) in a single center. The study included B-cell lymphoma patients who were 18 years or older and who had received DA-EPOCH at Moffitt Cancer Center from April 26, 2017 through August 10, 2019. The primary endpoint was hospital admissions during outpatient chemotherapy administration. Additional safety endpoints included hospitalizations between cycles, infectious complications, extravasations, drug spills, pump-malfunctions, and drug-related adverse events. Fifty-six patients received 219 cycles of DA-EPOCH with 193 cycles administered outpatient. Zero patients required hospitalization during outpatient administration of DA-EPOCH, resulting in 965 saved hospital days. Twenty-three patients (41%) were hospitalized between cycles, most commonly due to neutropenic fever (52%). No extravasations were documented throughout the study period. There were few incidences of drug spills or pump malfunctions. The authors concluded routine outpatient administration of DA-EPOCH is both safe and feasible. The study is limited by lack of concurrent comparison group.

Chen et al. (2020) investigated differences in quality of life (QoL) in esophageal squamous cell carcinoma (ESCC) patients who underwent inpatient chemotherapy (IPCT) or outpatient chemotherapy (OPCT) in a prospective cohort study. A total of 107 patients with ESCC were enrolled, including 53 patients in the IPCT group and 54 patients in the OPCT group. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Items (EORTC QLQ-C30) and Oesophageal Cancer Module (EORTC QLQ-OES18) were used to examine the QoL of the two groups. In addition, the differences in adverse events (AEs) were evaluated. The results of QLQ C-30 analysis showed that mean global QoL scores were similar between IPCT and OPCT groups, as were functional and symptom scales. There were no significant differences in the functional and symptom scales in the analysis of QLQ OES18 either. Most AEs of chemotherapy were grades 1-2, and the majority of patients tolerated the side effects; no statistically significant difference in AEs between these two groups was noted. The authors concluded that the health-related QoL and adverse events in ESCC patients who received IPCT or OPCT are similar and that OPCT is reasonable and safe in clinical practice. This study was limited by a small sample size, which may have not allowed to detect clinically significant differences, at a single institution with various chemotherapy interventions.

In a retrospective cohort study, Rodrigues et al. (2020) assessed the safety of consolidation with high-dose cytarabine in the outpatient setting. The authors retrospectively analyzed 39 patients who underwent consolidation with high dose cytarabine, between 2009 and 2018, at Ophir Loyola Hospital, in Belém, Brazil. Patients treated after 2015 were given high-dose cytarabine as outpatients due to the decision of medical staff. Twenty-seven patients received 76 cycles of cytarabine as outpatients; males were 48.14% of the total population, with a median age of approximately 45 years. The occurrence of delay between cycles was significantly lower among outpatients (48.14% vs. 83.33%, P = 0.04). There was no difference in relapse rates, transfusion requirements and non-relapse mortality between both groups. Hospitalization was required in 40.74% of patients during outpatient cycles and 18.51% of blood cultures were positive for pathogens. Non-relapse mortality was significantly higher among patients above 50 years old and treated on an outpatient basis (44.4% vs. 5.60%, P = 0.03). The authors concluded high-dose cytarabine administration on an outpatient basis appeared to be safe and effective in a low-income population at the Brazilian Amazon region, but toxicity seems to be increased for patients older than 50 years. This study was limited by a small sample size in a single tertiary hospital.

In a case series, Keshvani et al. (2019) explored the economic and psychological impacts of transitioning EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin)-based chemotherapy to an ambulatory infusion model. After receiving an initial cycle of chemotherapy in the hospital, study participants received a rituximab infusion at the outpatient infusion center on day one, followed by a combination solution of etoposide, vincristine, and doxorubicin that was replaced every 24 hours on days two to four. After 96 hours of continuous infusion, patients received a cyclophosphamide infusion at the clinic and received follow-up blood tests twice per week. From January 30, 2017, to January 30, 2018, 18 patients received 61
cycles of EPOCH. The patients reported improved QoL and a preference for home chemotherapy. They noted no chemotherapy vesicant extravasations and no unexpected adverse safety effects with outpatient chemotherapy infusion. The authors noted the study was limited by a 50% response rate on the patient survey and small sample size in a single center study.

In a cross-over trial, Cox et al. (2011) compared patient preference for IP versus OP treatment with high-dose cisplatin (HDC). Secondary outcomes included aspects of health-related quality of life, adverse events (dose delays and reductions, elevated creatinine and unplanned readmissions) and resource use. Eligible patients were starting chemotherapy with ≥ 2 cycles of HDC (≥ 100 mg/dose) and were suitable for OP treatment. Exclusion criteria included previous treatment with cisplatin, a history of renal impairment or symptomatic heart failure, and pregnancy or lactation. All patients received an IP cycle and OP cycle: the order was randomly allocated. Pre-hydration, anti-emetics and chemotherapy were identical for IP and OP. Post-hydration varied by group (3 L normal saline (NS) for IP, 2 L NS for OP). Fifty-nine patients were randomized, 53 completed two cycles of HDC. Most patients preferred OP treatment (36 vs 13, P = 0.002). There were no significant differences in patients' ratings of nausea, vomiting, fatigue, anxiety, depression or overall quality of life. Adverse events were few and unrelated to IP versus OP treatment: There were nine unplanned hospital admissions after the 53 IP chemotherapy cycles and seven after the 53 OP cycles (P = 0.428). Nursing time was longer for IP than OP (163 vs 104 min, P < 0.001). The authors concluded most patient preferred OP treatment and OP treatment appeared safe and used less resources. This study is limited by the small sample size in a single center.

Clinical Practice Guidelines

**American Society of Clinical Oncology (ASCO)**

The ASCO and the Oncology Nursing Society (ONS) worked together to create a set of chemotherapy administration safety standards. These guidelines were first published in 2009 and last updated in 2016 with the goal of providing a framework for best practice, reducing the risk of errors and increasing efficiency. The 2016 updated guidelines breaks the standards into four sections, creating a safe environment; treatment planning, patient consent, and education; ordering, preparing, dispensing, and administering chemotherapy; and lastly monitoring after administration of chemotherapy. These standards were intended to be used in a variety of settings and patient populations, but do not address specifically which setting is appropriate in different clinical situations (Neuss et al., 2017).

**U.S. Food and Drug Administration (FDA)**

This section is to be used for informational purposes only. FDA approval alone is not a basis for coverage.

The FDA reviews data on drug’s safety and efficacy. FDA approval occurs once the data has been reviewed by the Center for Drug Evaluation and Research (CDER) and it is determined that the benefit of the drug outweighs the potential risks in the intended population. Refer to the following website for information on FDA approved drugs: [http://www.accessdata.fda.gov/scripts/cder/daf/](http://www.accessdata.fda.gov/scripts/cder/daf/). (Accessed November 22, 2022)

**References**


### Policy History/Revision Information

<table>
<thead>
<tr>
<th>Date</th>
<th>Summary of Changes</th>
</tr>
</thead>
<tbody>
<tr>
<td>10/01/2023</td>
<td><strong>Application</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Individual Exchange Plans</strong></td>
</tr>
<tr>
<td></td>
<td>• Removed language indicating this Medical Policy does not apply to Individual Exchange benefit plans in the states of Massachusetts, Nevada, and New York</td>
</tr>
<tr>
<td></td>
<td><strong>Supporting Information</strong></td>
</tr>
<tr>
<td></td>
<td>• Archived previous policy version MP.02.14</td>
</tr>
</tbody>
</table>

### Instructions for Use

This Medical Policy provides assistance in interpreting UnitedHealthcare standard benefit plans. When deciding coverage, the member specific benefit plan document must be referenced as the terms of the member specific benefit plan may differ from the standard plan. In the event of a conflict, the member specific benefit plan document governs. Before using this policy, please check the member specific benefit plan document and any applicable federal or state mandates. UnitedHealthcare reserves the right to modify its Policies and Guidelines as necessary. This Medical Policy is provided for informational purposes. It does not constitute medical advice.

This Medical Policy may also be applied to Medicare Advantage plans in certain instances. In the absence of a Medicare National Coverage Determination (NCD), Local Coverage Determination (LCD), or other Medicare coverage guidance, CMS allows a Medicare Advantage Organization (MAO) to create its own coverage determinations, using objective evidence-based rationale relying on authoritative evidence (Medicare IOM Pub. No. 100-16, Ch. 4, §90.5).

UnitedHealthcare may also use tools developed by third parties, such as the InterQual criteria, to assist us in administering health benefits. UnitedHealthcare Medical Policies are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.